FDA OKs injectable form of non-steroidal anti-inflammatory
The U.S. Food and Drug Administration granted marketing approval for Metacam Injectable, a non-steroidal anti-inflammatory drug (NSAID), made by Boehringer Ingelheim Vetmedica (BI) and being distributed by Merial. Coupled with Metacam Oral Suspension, the injectable offers an effective source for relief of pain associate with canine osteoarthritis, the company says.
The U.S. Food and Drug Administration granted marketing approval for Metacam Injectable, a non-steroidal anti-inflammatory drug (NSAID), made by Boehringer Ingelheim Vetmedica (BI) and being distributed by Merial. Coupled with Metacam Oral Suspension, the injectable offers an effective source for relief of pain associate with canine osteoarthritis, the company says. With Metacam Injectable, (veterinarians) can be confident that they re beginning safe, effective and convenient therapy right in the exam room, says Dr. Steve Peterson, Metacam marketing manager, (BI).Metacam Injectable, the companies say, offers advantages over other injectable NSAIDs, such as:ӥ Quick, smooth injection The only injectable approved for subcutaneous and intravenous injection. A therapeutic dose less than half of other NSAID injectables. The most common side effects reported in field studies were vomiting and soft stool/diarrhea. Dogs should be evaluated for pre-existing conditions before treatment and monitored during therapy.
For fastest response call (888) 637-4251 or visit the Web site at www.merial.com.
